NASDAQ$LQDA
Liquidia Corporation · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Reported full-year financial results and provided a corporate update.
Liquidia Corporation reported its full-year 2020 financial results, highlighting the closure of the RareGen, LLC acquisition, executive team changes, and plans to respond to the LIQ861 CRL. The company is also focused on improving its balance sheet and cash spend, expecting positive contributions from Treprostinil Injection sales.
- Closed the acquisition and integration of RareGen, LLC, now known as Liquidia PAH, LLC, providing a commercial presence in PAH.
- Confirmed plan to submit response to LIQ861 CRL in mid-2021.
- Strengthened intellectual property tied to inhaled dry powder treprostinil with the issuance of patent No. 10,898,494.
- Reduced net annual cash spending to strengthen financial position by more than 40% compared to 2020 spending.
Headline financials
Revenue & EPS history
Liquidia · Revenue · Quarterly
$740K
Revenue by segment
Liquidia · $3.7M total across 1 segment · Q3 2023
- Promotion Agreement$3.7M+15.6%100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
+3.4%
Avg return
Earnings day
+5.4%
Avg return
5 days after
+3.5%
Avg return
30 days after
60%
18 / 30 earnings
Positive
+31.8%
Q2 2022
Best reaction
-13.3%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +25.4% | +34.5% | +54.1% | |
| Q4 2025 | +0.4% | +12.9% | +9.6% | |
| Q3 2025 | +8.8% | +7.1% | +38.5% | |
| Q1 2025 | -1.0% | +3.0% | +16.8% | |
| Q4 2024 | +1.2% | +6.2% | -6.9% | |
| Q3 2024 | -5.6% | -7.6% | +2.7% | |
| Q2 2024 | +2.9% | +10.4% | -17.7% | |
| Q1 2024 | -0.8% | +5.4% | +10.4% | |
| Q4 2023 | +9.6% | +11.3% | -0.2% | |
| Q3 2023 | -1.0% | -4.4% | +9.8% | |
| Q2 2023 | -6.3% | -8.9% | -7.5% | |
| Q1 2023 | +5.0% | +7.8% | +26.1% | |
| Q4 2022 | +13.5% | +13.2% | +6.3% | |
| Q3 2022 | +0.8% | -0.4% | +14.6% | |
| Q2 2022 | +31.8% | +34.5% | +9.9% | |
| Q1 2022 | +7.7% | +21.9% | -17.0% | |
| Q4 2021 | +11.2% | +9.7% | -17.8% | |
| Q3 2021 | +9.9% | +9.7% | +3.1% | |
| Q2 2021 | -0.8% | +11.8% | +16.4% | |
| Q1 2021 | -0.7% | +0.0% | -0.7% | |
| Q4 2020 | -7.4% | -6.6% | +2.2% | |
| Q3 2020 | +0.7% | -12.7% | -36.9% | |
| Q2 2020 | -13.3% | -8.5% | -23.3% | |
| Q1 2020 | +8.0% | +8.7% | +13.4% | |
| Q4 2019 | -1.5% | +1.7% | +54.5% | |
| Q3 2019 | +5.2% | +0.6% | +6.4% | |
| Q2 2019 | +6.4% | -0.7% | -40.6% | |
| Q1 2019 | -3.0% | -0.4% | +2.6% | |
| Q4 2018 | +3.0% | +3.1% | -43.8% | |
| Q3 2018 | -9.2% | -1.3% | +19.4% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro